Improving Protective Immunity Induced by DNA-Based Immunization: Priming with Antigen and GM-CSF-Encoding Plasmid DNA and Boosting with Antigen-Expressing Recombinant Poxvirus1 2

Intramuscular immunization with a naked DNA plasmid expressing the Plasmodium yoelii circumsporozoite protein (pPyCSP) protects mice against challenge with P. yoelii sporozoites. This protection can be improved either by coadministration of a plasmid expressing murine GM-CSF (pGMCSF) or by boosting with recombinant poxvirus expressing the PyCSP. We now report that combining these two strategies, by first mixing the priming dose of pPyCSP with pGMCSF and then boosting with recombinant virus, can substantially increase vaccine effectiveness. Not only were immune responses and protection improved but the pPyCSP dose could be lowered from 100 μg to 1 μg with little loss of immunogenicity after boost with recombinant poxvirus. Comparing mice primed by the 1-μg doses of pPyCSP plus 1 μg pGMCSF with mice primed by 1-μg doses of pPyCSP alone, the former were better protected (60% vs 0) and had higher concentrations of Abs (titers of 163, 840 vs 5, 120 by indirect fluorescent Ab test against sporozoites), more ex vivo CTL activity (25% vs 7% specific lysis), and more IFN-γ-secreting cells by enzyme-linked immunospot assay (1460 vs 280 IFN-γ spot-forming cells/106 cells). Priming with plasmid vaccine plus pGMCSF and boosting with recombinant poxviruses strongly improves the immunogenicity and protective efficacy of DNA vaccination and allows for significant reduction of dose.

[1]  S. Hoffman,et al.  IL-12 and NK cells are required for antigen-specific adaptive immunity against malaria initiated by CD8+ T cells in the Plasmodium yoelii model. , 1999, Journal of immunology.

[2]  D. Montefiori,et al.  Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations , 1999, Nature Medicine.

[3]  R. Sinden,et al.  Protection from Plasmodium berghei infection by priming and boosting T cells to a single class I‐restricted epitope with recombinant carriers suitable for human use , 1998, European journal of immunology.

[4]  S. Hoffman,et al.  Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. , 1998, Science.

[5]  S. Hoffman,et al.  A plasmid encoding murine granulocyte-macrophage colony-stimulating factor increases protection conferred by a malaria DNA vaccine. , 1998, Journal of immunology.

[6]  S. Hoffman,et al.  Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[7]  S. Hoffman,et al.  Research toward vaccines against malaria , 1998, Nature Medicine.

[8]  Marion Becker,et al.  Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara , 1998, Nature Medicine.

[9]  S. Rosenberg,et al.  Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. , 1997, Journal of the National Cancer Institute.

[10]  J. Waterkeyn,et al.  Sequential nucleic acid and recombinant adenovirus vaccination induces host‐protective immune responses against Taenia ovis infection in sheep , 1997, Parasite immunology.

[11]  F. Marshall,et al.  Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. , 1997, Cancer research.

[12]  D. Montefiori,et al.  Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting. , 1997, Virology.

[13]  James M. Wilson,et al.  Single immunizing dose of recombinant adenovirus efficiently induces CD8+ T cell-mediated protective immunity against malaria. , 1997, Journal of immunology.

[14]  S. Hoffman,et al.  Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8+ cell-, interferon gamma-, and nitric oxide-dependent immunity , 1996, The Journal of experimental medicine.

[15]  Division on Earth Guide for the Care and Use of Laboratory Animals , 1996 .

[16]  S. Hoffman,et al.  Plasmodium yoelii: 17-kDa hepatic and erythrocytic stage protein is the target of an inhibitory monoclonal antibody. , 1995, Experimental parasitology.

[17]  M. Esteban,et al.  Quantification of antigen specific CD8+ T cells using an ELISPOT assay. , 1995, Journal of immunological methods.

[18]  S. Hoffman,et al.  Induction of protective polyclonal antibodies by immunization with a Plasmodium yoelii circumsporozoite protein multiple antigen peptide vaccine. , 1995, Journal of immunology.

[19]  J. Yewdell,et al.  Influenza and vaccinia viruses expressing malaria CD8+ T and B cell epitopes. Comparison of their immunogenicity and capacity to induce protective immunity. , 1994, Journal of immunology.

[20]  S. Hoffman,et al.  Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[21]  S. Hoffman,et al.  Nitric oxide-mediated antiplasmodial activity in human and murine hepatocytes induced by gamma interferon and the parasite itself: enhancement by exogenous tetrahydrobiopterin , 1994, Infection and immunity.

[22]  P. Palese,et al.  Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[23]  R. Kurzrock,et al.  Very low doses of GM-CSF administered alone or with erythropoietin in aplastic anemia. , 1992, The American journal of medicine.

[24]  D. Tang,et al.  Genetic immunization is a simple method for eliciting an immune response , 1992, Nature.

[25]  S. Hoffman,et al.  IFN-gamma inhibits development of Plasmodium berghei exoerythrocytic stages in hepatocytes by an L-arginine-dependent effector mechanism. , 1991, Journal of immunology.

[26]  E. Estey,et al.  Effects of low doses of recombinant human granulocyte‐macrophage colony stimulating factor (GM‐CSF) in patients with myelodysplastic syndromes , 1991, British journal of haematology.

[27]  S. Hoffman,et al.  Monoclonal, but not polyclonal, antibodies protect against Plasmodium yoelii sporozoites. , 1991, Journal of immunology.

[28]  S. Hoffman,et al.  Sporozoite vaccine induces genetically restricted T cell elimination of malaria from hepatocytes. , 1989, Science.

[29]  D. Dale,et al.  Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: comparisons and potential for use in the treatment of infections in nonneutropenic patients. , 1999, The Journal of infectious diseases.

[30]  S. Hoffman Malaria vaccine development: a multi-immune response approach , 1996 .

[31]  A. Burgess,et al.  Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (2). , 1992, The New England journal of medicine.